Javed Butler, MD, MPH, MBA

Javed Butler, MD, MBA, discusses how aldosterone synthase inhibition could shift treatment across heart failure, CKD, and resistant hypertension.

Javed Butler, MD, MBA, on Aldosterone & Aldosterone Synthase Inhibitors in Cardiology

Aldosterone is drawing renewed scientific attention as a treatment target across 

. A new generation of aldosterone synthase inhibitors aims to lower aldosterone production directly, rather than blocking its receptor.

, Javed Butler, MD, MBA, president of the Baylor Scott & White Research Institute, examined where this approach fits in cardiorenal care. He weighed the evidence behind aldosterone synthase inhibition and its potential role in guideline-directed medical therapy for heart failure.

Recapping a session he led at the meeting, Butler emphasized how earlier aldosterone modulation data came largely from heart failure with reduced ejection fraction, along with post-myocardial infarction trials in reduced ejection fraction and heart failure. Noting evidence in chronic kidney disease and in prevention lagged, and findings in heart failure with preserved ejection fraction were contested.

Butler highlighted the unresolved question remains whether the aldosterone hypothesis itself is flawed or whether current receptor-targeted therapies leave meaningful residual benefit unharnessed. Lowering aldosterone levels directly through synthase inhibition offers a way to test the second possibility.

When asked on choosing between mineralocorticoid receptor antagonists and aldosterone synthase inhibitors, Butler highlighted this debate remains unsettled until further trial data becomes available. He called attention to earlier MRA trials enrolling few patients on SGLT2 inhibitors or GLP-1 receptor agonists, whereas the synthase inhibitor trials use active comparators in which every participant receives an SGLT2 inhibitor.

ClinicalTrials.Gov. A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure (LUMINARA). Clinicaltrials.gov. Published February 18, 2026. Accessed June 21, 2026. https://clinicaltrials.gov/study/NCT06299826 

Videos

The Role of Aldosterone & Aldosterone Synthase Inhibitors in Cardiology, with Javed Butler, MD, MBA

Navigating Access Barriers and Treatment Gaps in HFpEF Care

Access to care remains a major determinant of heart failure with preserved ejection fraction (HFpEF) outcomes. Panelists noted that disparities in insurance coverage, drug costs, and specialist availability limit the adoption of newer therapies such as finerenone.

They discussed how expanding formulary access, streamlining prior authorization processes, and improving clinician education can help close these gaps. Collaborative models between cardiology, primary care, and pharmacy teams were highlighted as effective tools for improving access.

Ultimately, addressing systemic barriers is essential for translating clinical advances into real-world benefit. The panel agreed that equity in care delivery must remain a central goal as HFpEF management continues to evolve.

The discussion concludes with strategies to overcome access barriers and ensure equitable implementation of novel HFpEF therapies.

Challenges With Combining Nonsteroidal MRAs and Treatment Adherence in HFpEF

Panelists discussed that although nonsteroidal mineralocorticoid receptor antagonists such as finerenone offer clear clinical advantages, treatment adherence remains a critical barrier to success. Complex regimens, frequent laboratory monitoring, and adverse effect concerns often hinder consistent use.

They emphasized simplifying care through patient education, digital reminders, and coordinated follow-up. Addressing cost and access issues is equally important to ensuring long-term persistence with therapy.

Panelists concluded that optimizing adherence requires aligning clinical simplicity with patient empowerment. When patients understand their treatment rationale and receive ongoing support, therapy success rates improve significantly.

Panelists address adherence challenges and the need for careful coordination when integrating nonsteroidal MRAs into multifaceted treatment plans.

Strategies for Prevention of HFpEF

Panelists highlighted prevention as the most powerful but underutilized strategy in heart failure with preserved ejection fraction (HFpEF) care. Because the condition often develops from metabolic and hypertensive pathways, early lifestyle modification can delay or prevent disease onset.

They discussed how weight management, exercise, and strict blood pressure control significantly lower HFpEF risk. Early use of cardioprotective agents such as sodium-glucose transporter 2 inhibitors in high-risk populations may also offer preventive benefits.

Panelists concluded that prevention requires both system-level and patient-level commitment. Integrating cardiovascular risk screening into routine care and emphasizing patient education could reduce the growing burden of HFpEF worldwide.

Experts highlight preventive approaches, including risk factor control and early therapeutic intervention, to mitigate HFpEF development.

Javed Butler, MD, MPH, MBA

Articles